Oligonucleotide Solid Nucleolipid Nanoparticles against Antibiotic Resistance of ESBL-Producing Bacteria.
CTX-M15 ß-lactamase
ESBL-producing E. coli
antibiotic resistance
nanocapsules
nucleic acids
nucleolipid
oligonucleotides
solid nanoparticles
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
27 Jan 2022
27 Jan 2022
Historique:
received:
08
12
2021
revised:
20
01
2022
accepted:
25
01
2022
entrez:
26
2
2022
pubmed:
27
2
2022
medline:
27
2
2022
Statut:
epublish
Résumé
Antibiotic resistance has become a major issue in the global healthcare system, notably in the case of Gram-negative bacteria. Recent advances in technology with oligonucleotides have an enormous potential for tackling this problem, providing their efficient intrabacterial delivery. The current work aimed to apply this strategy by using a novel nanoformulation consisting of DOTAU, a nucleolipid carrier, in an attempt to simultaneously deliver antibiotic and anti-resistance oligonucleotides. Ceftriaxone, a third-generation cephalosporin, was formulated with DOTAU to form an ion pair, and was then nanoprecipitated. The obtained solid nanocapsules were characterized using FT-IR, XRD, HPLC, TEM and DLS techniques and further functionalized by the anti-resistance ONα sequence. To obtain an optimal anti-resistance activity and encapsulation yield, both the formulation protocol and the concentration of ONα were optimized. As a result, monodispersed negatively charged nanoparticles of CFX-DOTAU-ONα with a molar ratio of 10:24:1 were obtained. The minimum inhibitory concentration of these nanoparticles on the resistant
Identifiants
pubmed: 35214036
pii: pharmaceutics14020299
doi: 10.3390/pharmaceutics14020299
pmc: PMC8876242
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Inserm Transfert
ID : CoPoC MAT-API-00391-A-02 and MAT-PI-18250-A-06
Commentaires et corrections
Type : ErratumIn
Références
Drug Resist Updat. 2000 Oct;3(5):303-311
pubmed: 11498398
J Phys Chem B. 2014 Jun 19;118(24):6570-85
pubmed: 24911942
Adv Drug Deliv Rev. 2013 Nov;65(13-14):1803-15
pubmed: 23892192
Colloids Surf B Biointerfaces. 2014 May 1;117:303-11
pubmed: 24667076
Drug Resist Updat. 2011 Apr;14(2):118-24
pubmed: 21435939
Bull World Health Organ. 1983;61(3):383-94
pubmed: 6603914
Nat Rev Microbiol. 2011 Nov 02;9(12):894-6
pubmed: 22048738
Int J Antimicrob Agents. 2014 Jun;43(6):485-96
pubmed: 24721232
J Antimicrob Chemother. 2009 Jun;63(6):1205-14
pubmed: 19329798
Clin Infect Dis. 1998 Aug;27 Suppl 1:S135-40; discussion S141-2
pubmed: 9710682
Nucleic Acid Ther. 2017 Jun;27(3):176-181
pubmed: 28080251
J Antimicrob Chemother. 2017 Aug 1;72(8):2145-2155
pubmed: 28541467
Antimicrob Resist Infect Control. 2019 Feb 12;8:36
pubmed: 30805183
Nat Chem Biol. 2011 Jun;7(6):348-50
pubmed: 21516114
Bioconjug Chem. 2009 Sep;20(9):1765-72
pubmed: 19711898
Pharmacol Res Perspect. 2021 Aug;9(4):e00849
pubmed: 34331383
Curr Opin Microbiol. 2016 Oct;33:47-55
pubmed: 27375107
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13853-8
pubmed: 11095745
Curr Med Chem. 2013;20(10):1232-40
pubmed: 23432585
Antimicrob Agents Chemother. 2009 Jul;53(7):2871-8
pubmed: 19433567
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21
pubmed: 17379663
Nat Med. 2004 Dec;10(12 Suppl):S122-9
pubmed: 15577930
Bioconjug Chem. 2016 Mar 16;27(3):569-75
pubmed: 26751997
Int J Antimicrob Agents. 2002 May;19(5):413-26
pubmed: 12007850
J Pharm Sci. 2019 Aug;108(8):2805-2813
pubmed: 30878515
Antimicrob Agents Chemother. 2006 May;50(5):1869-71
pubmed: 16641464
Transl Res. 2020 Sep;223:89-106
pubmed: 32522669
Eur J Med Chem. 2012 Nov;57:429-40
pubmed: 22818038
Nucleic Acids Res. 2021 May 7;49(8):4705-4724
pubmed: 33849070
Curr Med Chem. 2010;17(6):585-94
pubmed: 20015030
Bull World Health Organ. 2011 Feb 1;89(2):88-9
pubmed: 21346918
Pharm Res. 2013 Apr;30(4):959-67
pubmed: 23292220
Chem Commun (Camb). 2017 Oct 19;53(84):11560-11563
pubmed: 28990612
Sci Rep. 2020 Jan 23;10(1):1054
pubmed: 31974472
Nanoscale Res Lett. 2018 Jan 11;13(1):17
pubmed: 29327307
J Antimicrob Chemother. 2017 Mar 1;72(3):782-790
pubmed: 27999041
Nature. 2015 May 28;521(7553):402-3
pubmed: 26017421
ACS Appl Mater Interfaces. 2021 Oct 13;13(40):47987-47995
pubmed: 34585574
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11915-20
pubmed: 18695239
J Glob Antimicrob Resist. 2021 Mar;24:285-295
pubmed: 33484895
J Control Release. 2011 Dec 10;156(2):128-45
pubmed: 21763369
Expert Opin Drug Deliv. 2012 Nov;9(11):1325-32
pubmed: 22924701
J Intern Med. 2010 Jan;267(1):44-53
pubmed: 20059643
Nucleic Acids Res. 2004 Jul 22;32(13):e109
pubmed: 15272050
Bioconjug Chem. 2006 Mar-Apr;17(2):466-72
pubmed: 16536479
J Pharm Biomed Anal. 2005 Sep 15;39(3-4):752-6
pubmed: 15967622
Adv Pharm Bull. 2015 Sep;5(3):305-13
pubmed: 26504751
J Control Release. 2017 Jul 28;258:1-9
pubmed: 28472637
Chem Commun (Camb). 2015 May 18;51(40):8492-5
pubmed: 25891472
Biochim Biophys Acta. 2001 Nov 1;1515(1):44-54
pubmed: 11597351
Mol Ther. 2006 Oct;14(4):476-84
pubmed: 16829204
Nanomedicine. 2018 Apr;14(3):745-758
pubmed: 29341934
Anal Bioanal Chem. 2018 Nov;410(29):7711-7721
pubmed: 30267273
Int J Pharm. 2018 Jan 30;536(1):283-291
pubmed: 29198808
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11493-8
pubmed: 8876163
J Pharm Sci. 2005 Nov;94(11):2541-8
pubmed: 16200559
J Antibiot (Tokyo). 2012 Mar;65(3):129-134
pubmed: 22186597
Antimicrob Agents Chemother. 2018 Nov 26;62(12):
pubmed: 30348664
Front Microbiol. 2016 Mar 24;7:373
pubmed: 27047482
FEMS Immunol Med Microbiol. 2010 Dec;60(3):275-82
pubmed: 20955466
Adv Mater. 2018 Mar;30(11):
pubmed: 29341288